Oxford–AstraZeneca COVID-19 vaccine
Oxford–AstraZeneca COVID-19 vaccine
Viral vector vaccine for prevention of COVID-19.
No account needed. By playing, you confirm you're 13 or older and agree to the Terms of use.
No owners yet
Category: Empty
- 0 owners
- 0 copies
- 0 pulls
- Wishlisted
- 0
- In 0 albums
- On 0 showcases
- Market listings
- 0
Not sold on the market yet.
Readers' pathsAug 2026 – Oct 2026
Readers go next to
Share of the 2,076 clicks on its links
AstraZeneca
Swedish-British pharmaceutical company.
13%
Viral vector vaccine
Type of vaccine.
11%
COVID-19 vaccine
Vaccine against SARS-CoV-2.
11%
Embolic and thrombotic events after COVID-19 vaccination
Post vaccination adverse effects.
6.5%
Guillain–Barré syndrome
Autoimmune disease.
3.9%
Sarah Gilbert
English vaccinologist (born 1962).
3.8%
Pfizer–BioNTech COVID-19 vaccine
Type of vaccine for humans.
3.7%
European Commission–AstraZeneca COVID-19 vaccine dispute
Dispute between the European Union and AstraZeneca.
3.7%
SARS-CoV-2
Virus that causes COVID-19.
3.6%
Adenoviridae
Family of viruses.
3.3%
Readers come from
Share of the 2,798 readers arriving from another article
COVID-19 vaccine
Vaccine against SARS-CoV-2.
8.2%
Sputnik V COVID-19 vaccine
Russian vaccine against COVID-19.
7.1%
AstraZeneca
Swedish-British pharmaceutical company.
6.6%
COVID-19 pandemic
Pandemic caused by SARS-CoV-2.
6.2%
COVID-19 vaccination in India
Immunisation programme against COVID-19 in India.
4.4%
United Kingdom
Country in Northwestern Europe.
4.3%
COVID-19 pandemic in India
3.9%
Copley Medal
Award given by the Royal Society of London.
3.5%
Eric Clapton
English musician (born 1945).
3.2%
COVAX
Initiative to provide COVID-19 vaccines.
2.6%